<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874376</url>
  </required_header>
  <id_info>
    <org_study_id>PHY2110</org_study_id>
    <nct_id>NCT04874376</nct_id>
  </id_info>
  <brief_title>PMCF Retrospective Study Outcomes of a Premium Monofocal IOL</brief_title>
  <acronym>PHY2110</acronym>
  <official_title>Clinical Study to Investigate Visual Performance, Contrast Sensitivity and Patient Satisfaction After Implantation of a Premium Monofocal Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beaver-Visitec International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>targomedGmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beaver-Visitec International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric, retro- / prospective, open-label, observational PMCF study to investigate&#xD;
      visual performance, contrast sensitivity and patient satisfaction after mono- or bilateral&#xD;
      implantation of Isopure 1.2.3. intraocular lenses following cataract surgery.&#xD;
&#xD;
      The study treatment itself is not part of this observational clinical investigation. Only&#xD;
      patients that already have been implanted with the device under investigation qualify for&#xD;
      this retro- prospective observational clinical study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicentric, retro- / prospective, open-label, observational PMCF study to&#xD;
      investigate visual performance, contrast sensitivity and patient satisfaction after mono- or&#xD;
      bilateral implantation of Isopure 1.2.3. intraocular lenses following cataract surgery.&#xD;
&#xD;
      The study treatment itself is not part of this observational clinical investigation. Only&#xD;
      patients that already have been implanted with the device under investigation qualify for&#xD;
      this retro- prospective observational clinical study.&#xD;
&#xD;
      Isopure 1.2.3. is CE approved and commercially available in the countries this clinical&#xD;
      investgation is being carried out. The investigational device and all study products,&#xD;
      including the devices used for the study examinations, will be used within the intended use&#xD;
      specifications from the manufacturer. In addition, no invasive or other burdening&#xD;
      examinations will occur for the patient.&#xD;
&#xD;
      The study will be carried out in up to five clinical centers in Spain. The device under&#xD;
      investigation (Isopure 1.2.3.) is a hydrophobic, glistening-free, acrylic Premium Monofocal&#xD;
      intraocular lens (IOL) manufactured by the sponsor of this study, PhysIOL sa/nv.&#xD;
&#xD;
      Subjects participating in the trial will attend a total of maximum 1 study visit (from 120&#xD;
      days post-operative). This study visit will be minimum 20 days after the surgery of the 2nd&#xD;
      eye. Subjects would have the option for unscheduled visits if required medically.&#xD;
&#xD;
      The primary performance endpoint is to show that the monocular Best Corrected Distance Visual&#xD;
      Acuity (CDVA) measured in the study group is statistically non-inferior to outcomes of the&#xD;
      monofocal parent lens Micropure 1.2.3. The comparative data is used from the latest Clinical&#xD;
      Evaluation Report (CER) for the monofocal Micropure 1.2.3. lens. To avoid bias, only the&#xD;
      first implanted eye will be considered for this calculation. Data interim analyses will be&#xD;
      done after the last patient finished the 1 study visit postoperative examination to support&#xD;
      the study publication plan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>monocular Best Corrected Distance Visual Acuity (CDVA) under photopic light conditions on the first implanted eye.</measure>
    <time_frame>From 120 days postoperative</time_frame>
    <description>No statistically significant difference between the monocular CDVA from 4 months follow up visit when compared to the parent IOL (Micropure 1.2.3). A significance level of 0.025 or lower (p &lt; 0.025) will be considered statistically significant. CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2018.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Cataract</condition>
  <condition>Lens Opacities</condition>
  <arm_group>
    <arm_group_label>IOL retrospective data collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm: Premium Monofocal intraocular lens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOL implantation experimental (Isopure 1.2.3.)</intervention_name>
    <description>Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection</description>
    <arm_group_label>IOL retrospective data collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Male or female adults ages 45 years or older on the day of treatment that were mono-&#xD;
             or bilaterally implanted with Isopure 1.2.3. intraocular lens minimum 120 days before&#xD;
             the study visit;&#xD;
&#xD;
          -  Maximum time between first and second eye treatment: 45 days (this accounts for&#xD;
             bilateral implantations only);&#xD;
&#xD;
          -  Capability to understand and sign an IRB approved informed consent form and privacy&#xD;
             authorization;&#xD;
&#xD;
          -  Clear intraocular media;&#xD;
&#xD;
          -  Minimum set of retrospective preoperative and intraoperative data available as&#xD;
             outlined in the examination matrix;&#xD;
&#xD;
          -  Willing and able to conform to the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Age of patient &lt;45 years at the day of surgery;&#xD;
&#xD;
          -  Time between first and second eye treatment: &gt;45 days (this accounts for bilateral&#xD;
             implantations only);&#xD;
&#xD;
          -  Subjects who underwent previous intraocular or corneal surgery other than IOL&#xD;
             implantation;&#xD;
&#xD;
          -  Subjects with diagnosed degenerative visual disorders (e.g. AMD or CME);&#xD;
&#xD;
          -  Subjects in whom in-the-bag implantation was not possible;&#xD;
&#xD;
          -  Subjects in whom surgical complications occurred (e.g. posterior rupture).&#xD;
&#xD;
          -  Subjects showing glaucoma;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gonzalo Bernabeu Arias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HM Monteprincipe, HM Vallés, Madrid, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jochen Kandulla, PhD</last_name>
    <phone>+49 176 55708170</phone>
    <email>jochen.kandulla@targomed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca McQuaid, PhD</last_name>
    <phone>+353871212615</phone>
    <email>rmcquaid@bvimedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oftalvist, Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Tana Rivero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vithas, Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Luis Rincon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Baviera</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Bilbao-Calabuig, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HM Monteprincipe</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gonzalo Bernabeu Arias, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HM Vallés</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonzalo Bernabeu Arias, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augenklinik, Palma de Mallorca</name>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastien Beckers, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Morlock R, Wirth RJ, Tally SR, Garufis C, Heichel CWD. Patient-Reported Spectacle Independence Questionnaire (PRSIQ): Development and Validation. Am J Ophthalmol. 2017 Jun;178:101-114. doi: 10.1016/j.ajo.2017.03.018. Epub 2017 Mar 22.</citation>
    <PMID>28341605</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular Lens</keyword>
  <keyword>Premium</keyword>
  <keyword>hydrophobic</keyword>
  <keyword>IOL</keyword>
  <keyword>monofocal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

